Newsfeeds - Spark Newswire - Page 2

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday

Today, 4:11 AM

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.

Read More

3 minute read

Kymera Therapeutics Presented Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at ASH 2022; Said A Single Dose of KT-253 Induced Rapid Apoptosis and Sustained Tumor Regression in…

By Charles Gross

Today, 4:11 AM

Kymera Therapeutics, Inc.

Read More

2 minute read

JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday

Today, 4:11 AM

Morgan Stanley raised JPMorgan Chase & Co. (NYSE:JPM) price target from $126 to $153. . Morgan Stanley analyst…

Read More

1 minute read

Credit Suisse Downgrades Kymera Therapeutics to Neutral, Lowers Price Target to $32

By Benzinga Newsdesk

Today, 4:11 AM

Credit Suisse analyst Richard Law downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Neutral and lowers the price target from $47 to $32.

Read More

2 minute read

Analyst Ratings

Where Kymera Therapeutics Stands With Analysts

By Benzinga Insights

Today, 4:11 AM

Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter:

Read More

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 8, 2022

By Benzinga Insights

Today, 4:11 AM

Upgrades

Read More

1 minute read

Raymond James Initiates Coverage On Kymera Therapeutics with Market Perform Rating

By Benzinga Newsdesk

Today, 4:11 AM

Raymond James analyst Steven Seedhouse initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Market Perform rating.

Read More

1 minute read

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38

By Benzinga Newsdesk

Today, 4:11 AM

Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $37 to $38.

Read More

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

Today, 4:11 AM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Read More

3 minute read

Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 4:11 AM

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…